GlassScriptPhysician profile
Colleen Brown
NPI 1154656890
$3,932.84
in general payments reported to CMS, 2019-2025
44 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,197 · 2022: $899 · 2023: $732 · 2024: $782 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.92 | 2021-2025 | |
| Novo Nordisk INC | $386.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $327.10 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Galderma Laboratories, L.P. | $193.67 | 2023-2025 | Dysport |
| Amgen INC. | $168.63 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $157.66 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $154.86 | 2021-2023 | Ajovy |
| Neos Therapeutics, LP | $142.62 | 2021-2024 | Adzenys Xr-Odt |
| Astellas Pharma US INC | $130.25 | 2023-2025 | Veozah |
| Gilead Sciences, INC. | $120.45 | 2023-2025 | Veklury |
| Biohaven Pharmaceutical Holding Company LTD. | $114.73 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.21 | 2021-2025 | |
| Pfizer INC. | $97.84 | 2023-2025 | |
| Lilly USA, LLC | $90.56 | 2021-2024 | Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $82.57 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.